NO961979D0 - Estramustin formuleringer med forbedrede farmasöytiske egenskaper - Google Patents

Estramustin formuleringer med forbedrede farmasöytiske egenskaper

Info

Publication number
NO961979D0
NO961979D0 NO961979A NO961979A NO961979D0 NO 961979 D0 NO961979 D0 NO 961979D0 NO 961979 A NO961979 A NO 961979A NO 961979 A NO961979 A NO 961979A NO 961979 D0 NO961979 D0 NO 961979D0
Authority
NO
Norway
Prior art keywords
estramustine
pct
date
formulations
pharmaceutical properties
Prior art date
Application number
NO961979A
Other languages
English (en)
Other versions
NO314438B1 (no
NO961979L (no
Inventor
Alessandro Martini
Giuseppe Maccari
Lorena Muggetti
Giuseppe Colombo
Giovanni Buzzi
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO961979D0 publication Critical patent/NO961979D0/no
Publication of NO961979L publication Critical patent/NO961979L/no
Publication of NO314438B1 publication Critical patent/NO314438B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO19961979A 1994-09-22 1996-05-14 Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav NO314438B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419153A GB9419153D0 (en) 1994-09-22 1994-09-22 Estramustine formulations with improved pharmaceutical properties
PCT/EP1995/003438 WO1996009072A1 (en) 1994-09-22 1995-09-01 Estramustine formulations with improved pharmaceutical properties

Publications (3)

Publication Number Publication Date
NO961979D0 true NO961979D0 (no) 1996-05-14
NO961979L NO961979L (no) 1996-05-14
NO314438B1 NO314438B1 (no) 2003-03-24

Family

ID=10761769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961979A NO314438B1 (no) 1994-09-22 1996-05-14 Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav

Country Status (27)

Country Link
US (1) US5712260A (no)
EP (1) EP0730474B1 (no)
JP (1) JP3568957B2 (no)
KR (1) KR960705587A (no)
CN (1) CN1135719A (no)
AT (1) ATE219378T1 (no)
AU (1) AU698425B2 (no)
CA (1) CA2174968A1 (no)
CZ (1) CZ292125B6 (no)
DE (1) DE69527129T2 (no)
DK (1) DK0730474T3 (no)
ES (1) ES2179115T3 (no)
FI (1) FI962120A0 (no)
GB (1) GB9419153D0 (no)
HU (1) HUT75935A (no)
IL (1) IL115376A (no)
MX (1) MX9601852A (no)
MY (1) MY115689A (no)
NO (1) NO314438B1 (no)
NZ (1) NZ292895A (no)
PL (1) PL183132B1 (no)
PT (1) PT730474E (no)
RU (1) RU2179036C2 (no)
TW (1) TW496739B (no)
UA (1) UA48126C2 (no)
WO (1) WO1996009072A1 (no)
ZA (1) ZA957938B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
ITMI20031015A1 (it) * 2003-05-20 2004-11-21 Naxospharma S R L Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299104A (en) * 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
JPH09505832A (ja) 1997-06-10
AU698425B2 (en) 1998-10-29
TW496739B (en) 2002-08-01
RU2179036C2 (ru) 2002-02-10
CZ292125B6 (cs) 2003-08-13
IL115376A (en) 1999-05-09
FI962120A (fi) 1996-05-20
EP0730474A1 (en) 1996-09-11
MY115689A (en) 2003-08-30
ES2179115T3 (es) 2003-01-16
EP0730474B1 (en) 2002-06-19
PT730474E (pt) 2002-11-29
CN1135719A (zh) 1996-11-13
NO314438B1 (no) 2003-03-24
MX9601852A (es) 1997-03-29
CA2174968A1 (en) 1996-03-28
HU9601738D0 (en) 1996-08-28
KR960705587A (ko) 1996-11-08
AU3519995A (en) 1996-04-09
HUT75935A (en) 1997-05-28
PL314584A1 (en) 1996-09-16
DK0730474T3 (da) 2002-09-23
GB9419153D0 (en) 1994-11-09
FI962120A0 (fi) 1996-05-20
ZA957938B (en) 1996-04-18
CZ145696A3 (en) 1996-08-14
IL115376A0 (en) 1995-12-31
DE69527129D1 (de) 2002-07-25
ATE219378T1 (de) 2002-07-15
WO1996009072A1 (en) 1996-03-28
NZ292895A (en) 1998-04-27
DE69527129T2 (de) 2003-03-06
UA48126C2 (uk) 2002-08-15
JP3568957B2 (ja) 2004-09-22
US5712260A (en) 1998-01-27
PL183132B1 (pl) 2002-05-31
NO961979L (no) 1996-05-14

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
HUP0001170A2 (hu) Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
NO961979L (no) Estramustin formuleringer med forbedrede farmasöytiske egenskaper
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
KR970704685A (ko) 신경이완제로서 유용한 N-치환 아자비시클로헵탄 유도체(N-Substituted Azabicycloheptane Derivatives Useful as Neuroleptics)
NO950177D0 (no) Farmakologisk aktive erivater
HUP0203045A2 (hu) Epesavval képezett 4-benzil-amino-kinolin konjugátumok és hetero-analógjai, valamint eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények, és ezek alkalmazása
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
IT1252169B (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione, e procedimento per la preparazione dei suddetti principi attivi
RU98114985A (ru) Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы
RU97113700A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики ожирения